The first mRNA vaccine against RSV in adults has already been approved in Europe and the United States

mResvia, developed by Moderna, is the first mRNA vaccine authorized in the EU for a disease other than COVID-19

With CE and FDA information

The European Commission today has given permission to mRNA vaccine “mResvia” to vaccination for adults over 60 against lower respiratory disease, caused by respiratory syncytial virus (RSV) infection.

The US Food and Drug Administration (FDA) approved mResvia in June 2024. With this vaccine, three are available for adults 60 years of age and older: https://espanol.cdc.gov/rsv/vaccines/older-adults.html

RSV is a common respiratory virus, which usually causes mild symptoms, but can seriously affect vulnerable people, including older adults.

Stella KyriakidesThe Health and Food Safety Commissioner said: “Vaccination saves lives. In a strong European Health Union, we are determined to ensure that everyone has access to the protection they need against serious diseases. “This approval of the first mRNA vaccine against RSV clearly demonstrates the importance of innovation in protecting the health of our citizens.”

Has permission Resvia It takes place before the autumn/winter season, when respiratory diseases such as RSV tend to be at their peak across the EU. It happens after a advanced scientific evaluation made by the European Medicines Agency (EMA) in June 2024. It is now up to the national authorities of each Member State to decide whether and how to use the vaccine, according to their national vaccination plans.

mResvia, developed by Moderna, is the first mRNA vaccine authorized in the EU for a disease other than COVID-19. In 2023, the commission authorized other RSV vaccines to protect vulnerable groups, including infants.

With information from the EC | FDA